原发性肝癌介入治疗中拉米夫定的预防性应用疗效观察

Efficacy of lamivudine of prophylactic use in the interventional therapy of primary liver cancer

目的观察肝癌介入治疗中拉米夫定的预防性应用疗效。方法选取我院2010年9月-2012年8月收治的130例原发性肝癌患者,随机分为两组,对照组患者接受单纯介入治疗,实验组患者在介入治疗时辅以拉米夫定治疗。术后随访2年,对比分析两组患者治疗前后血清HBV-DNA水平的变化和死亡率的差异性。结果经过治疗后患者血清HBVDNA水平均较治疗前升高,实验组升高幅度明显小于对照组,经t检验分析发现组间比较差异有统计学意义（P〈0.05）。随访期间实验组患者死亡率明显低于对照组,经卡方检验分析发现组间比较差异有统计学意义（P〈0.05）。结论肝癌介入治疗对乙肝病毒产生激发作用,抗病毒药物拉米夫定可预防和控制肝癌介入期间乙肝病毒活跃程度,从而保障抗肿瘤治疗效果,延长患者生存时间。

Objective To observe efficacy of lamivudine of prophylactic use in the interventional therapy of liver cancer. Methods Selected 130 cases with primary liver cancer in our hospital from Sep 2010 to Aug 2012,randomly divided into two groups. The control group received simple intervention and experimental group received simple intervention combined with lamivudine. Patients were followed up 2 years after operation. Compared and analyzed serum HBV-DNA level changes and the differences in mortality rates of the patients before and after treatment in the two groups. Results Serum HBV-DNA level of patients was higher after treatment than before treatment, the range of experimental group increased significantly less than the control group,there was statistically significant difference between two groups after t test （P〈0.05）. Mortality of experimental group was significantly lower than the control group during the follow-up period, there was statistically significant difference between the two groups afterx2 test （P〈0.05）. Conclusion The interventional therapy of liver cancer can stimulate hepatitis B virus （HBV） ,lamivudine can prevent and control the activity of HBV during intervention period of liver cancer,so as to safeguard curative effect and prolong the survival time of patients.